R42

Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of various biological substances, including proteins, DNA, and small molecules. The company's innovative diagnostic analyzers and kits simplify the analysis of these biomolecules, making them valuable tools for pharmaceutical research and manufacturing. By enabling researchers to conduct sensitive, rapid, and near real-time medical diagnoses, Abselion enhances the understanding of biomolecular interactions, particularly in protein interaction analysis. This focus on efficiency and accuracy positions Abselion as a key player in the field of biosensing technology.

Healx is a biotechnology company specializing in the development of treatments for rare diseases through the use of generative artificial intelligence. By employing advanced AI and machine learning technologies, Healx focuses on identifying potential drug candidates and repurposing existing medications for new therapeutic applications. This approach takes advantage of the established safety profiles of known drugs, thereby minimizing the risks and costs typically associated with creating new pharmaceuticals from scratch. Through its innovative platform, Healx aims to accelerate the development of novel treatments, addressing the unmet medical needs of patients suffering from rare diseases worldwide.

Xwatts is a developer of intelligent energy management software aimed at helping commercial buildings minimize costs and reduce emissions. The company's system continuously analyzes usage patterns, environmental conditions, and market data to optimize electricity consumption. By providing building owners with the tools to take direct control of their distributed energy assets, Xwatts enables the integration of historical usage data with real-time market insights. This functionality allows building management systems to effectively evaluate and schedule energy assets, ultimately leading to significant reductions in electricity consumption costs.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Reservoir Neuroscience, Inc. is a biopharmaceutical company focused on developing innovative therapeutics aimed at repairing the blood-brain barrier and restoring vascular function in the brain. Founded in 2019 and located in Emeryville, California, the company targets age-related cognitive impairments and neurological disorders such as Alzheimer's disease. Its therapeutics are designed to address dysfunctional blood vessels in the brain, thereby improving disease outcomes for patients and enhancing their access to effective medical interventions.

Soopra is a platform that allows experts to create AI personas to interact with their audiences 24/7, providing a new, scalable way to monetize their knowledge.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunctions related to neurological diseases, particularly higher-frequency migraines and conditions like Alzheimer's disease. The company creates and clinically tests medical foods designed to enhance brain energetics by providing ketone bodies as an alternative energy source when glucose utilization is impaired. Headquartered in the Technologie Park Basel, KetoSwiss operates within a vibrant ecosystem of academic research and life sciences innovation, positioning itself at the forefront of dietary preventive therapies for neurological conditions.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunctions related to neurological diseases, particularly higher-frequency migraines and conditions like Alzheimer's disease. The company creates and clinically tests medical foods designed to enhance brain energetics by providing ketone bodies as an alternative energy source when glucose utilization is impaired. Headquartered in the Technologie Park Basel, KetoSwiss operates within a vibrant ecosystem of academic research and life sciences innovation, positioning itself at the forefront of dietary preventive therapies for neurological conditions.

Silveray specializes in the development of affordable large-area direct conversion detectors for the X-ray imaging market. The company employs advanced technology that utilizes nanoparticle-based X-ray conversion materials, produced as semiconductor ink, which are then deposited onto a pixel backplane. This innovative approach enables high-performance X-ray imaging and generates an electrical current in response to detected X-ray photons. By focusing on sustainability and cost-effectiveness, Silveray aims to enhance imaging capabilities for healthcare and various industries.

WiseWorks is a meeting automation platform that assists corporate governance professionals in streamlining their workflows and minimizing time spent on costly tasks. The company has developed a communications intelligence platform tailored for financial institutions, enabling them to extract essential insights from audio and video interactions. This platform automatically joins records, transcribes, and analyzes communications, thus enhancing existing workflows and providing organizations with critical insights to mitigate risks. By automating these processes, WiseWorks aims to improve efficiency and support decision-making within organizations.

Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Stamp Free is a digital postage stamp company that offers innovative postage solutions through its mobile application. The platform allows both personal and business customers to purchase digital stamps directly on their smartphones, streamlining the process of sending letters and parcels. By utilizing artificial intelligence, the app eliminates the need for physical postage stamps or printed labels, enabling users to post items and manage returns conveniently. This technology simplifies mailing processes by providing information on the correct postage and services needed, making it easier for consumers and businesses to handle their mailing requirements efficiently.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Bounce Imaging, Inc. specializes in the manufacturing of tactical throwable cameras equipped with multiple lenses and sensors, designed primarily for use by police and firefighters. The company's innovative products enable first responders to safely assess hazardous environments remotely, providing real-time video and sensor data while maintaining stability during movement. In addition to its camera systems, Bounce Imaging offers a variety of accessories, including pole attachments, tethers, car chargers, headsets, wrist straps, and magnetic mounts. The company also provides cloud-based services that encompass technical consulting, design and implementation support, and troubleshooting for imaging and processing hardware. Founded in 2012, Bounce Imaging is headquartered in Buffalo, New York.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

ExSeed Health Limited, based in London, United Kingdom, specializes in home sperm testing solutions designed to assess fertility through sperm count and motility. The company offers a sperm testing device that utilizes micro-optic technology for accurate measurement of sperm quality, complemented by an intelligent lifestyle app. This app provides personalized lifestyle intervention supplements based on scientifically researched data, empowering users to enhance their reproductive health. Founded in 2017, ExSeed Health markets its products both online and in physical stores, making it accessible for individuals seeking to evaluate and improve their sperm quality in the privacy of their own homes.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

VividQ Limited is a software company specializing in the development of a framework that enables the generation, compression, and transmission of 3D holographic images and video. The company offers several key products, including VividQ Capture, which standardizes 3D data for holographic display, and VividQ Squeeze, a compression solution for point cloud data storage. Additionally, VividQ Core facilitates multi-user interactions with holograms, while VividQ View allows developers to integrate various spatial light modulators into their systems. The company's technology is utilized across various sectors, including consumer electronics, augmented and virtual reality, automotive displays, and immersive simulations. Founded in 2015 and based in Cambridge, United Kingdom, VividQ collaborates with leading original equipment manufacturers to integrate its advanced software and hardware solutions into next-generation consumer devices, aiming to create a seamless blend of real and virtual experiences.

Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of various biological substances, including proteins, DNA, and small molecules. The company's innovative diagnostic analyzers and kits simplify the analysis of these biomolecules, making them valuable tools for pharmaceutical research and manufacturing. By enabling researchers to conduct sensitive, rapid, and near real-time medical diagnoses, Abselion enhances the understanding of biomolecular interactions, particularly in protein interaction analysis. This focus on efficiency and accuracy positions Abselion as a key player in the field of biosensing technology.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Stamp Free is a digital postage stamp company that offers innovative postage solutions through its mobile application. The platform allows both personal and business customers to purchase digital stamps directly on their smartphones, streamlining the process of sending letters and parcels. By utilizing artificial intelligence, the app eliminates the need for physical postage stamps or printed labels, enabling users to post items and manage returns conveniently. This technology simplifies mailing processes by providing information on the correct postage and services needed, making it easier for consumers and businesses to handle their mailing requirements efficiently.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Exogene is a biotechnology company focused on advancing T-cell receptor (TCR)-based cancer immunotherapies for solid tumors. By integrating deep learning with high-throughput TCR-antigen screening, Exogene aims to efficiently identify new tumor targets that are common among cancer patients. The company is developing a computational platform designed to discover effective and safe TCRs against these targets, facilitating their therapeutic application. This innovative approach allows for the rapid and cost-effective development of TCR-based immunotherapies, ultimately supporting healthcare providers in creating cell therapies that enhance the immune system's ability to combat cancer.